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The Sm proteins B/B*, D1, D2, D3, E, F, and G are
components of the small nuclear ribonucleoproteins U1,
U2, U4/U6, and U5 that are essential for the splicing of
pre-mRNAs in eukaryotes. D1 and D3 are among the
most common antigens recognized by anti-Sm autoanti-
bodies, an autoantibody population found exclusively in
patients afflicted with systemic lupus erythematosus.
Here we demonstrate by protein sequencing and mass
spectrometry that all arginines in the C-terminal argin-
ine-glycine (RG) dipeptide repeats of the human Sm pro-
teins D1 and D3, isolated from HeLa small nuclear ribo-
nucleoproteins, contain symmetrical dimethylarginines
(sDMAs), a posttranslational modification thus far only
identified in the myelin basic protein. The further finding
that human D1 individually overexpressed in baculovi-
rus-infected insect cells contains asymmetrical dimethyl-
arginines suggests that the symmetrical dimethylation
of the RG repeats in D1 and D3 is dependent on the
assembly status of D1 and D3. In antibody binding stud-
ies, 10 of 11 anti-Sm patient sera tested, as well as the
monoclonal antibody Y12, reacted with a chemically
synthesized C-terminal peptide of D1 containing sDMA,
but not with peptides containing asymmetrically modi-
fied or nonmodified arginines. These results thus dem-
onstrate that the sDMA-modified C terminus of D1 forms
a major linear epitope for anti-Sm autoantibodies and
Y12 and further suggest that posttranslational modifica-
tions of Sm proteins play a role in the etiology of sys-
temic lupus erythematosus.
The small nuclear ribonucleoproteins (snRNPs)1 U1, U2, U5,
and U4/U6 are the major functional constituents of the spliceo-
some, a nuclear multicomponent complex that catalyzes the
splicing of nuclear pre-mRNA in eukaryotes (1). The UsnRNPs
consist of one (in the case of U1, U2, and U5) or two (in the case
of U4/U6) UsnRNAs and at least 50 distinct proteins (2). These
proteins can be divided into two groups: the Sm proteins B/B9,
D1, D2, D3, E, F, and G, found in each of the UsnRNPs, and the
specific proteins that are associated with only one of the Us-
nRNP particles.
The Sm proteins play a key role in the biogenesis of the
UsnRNPs. In the cytoplasm, the Sm proteins form RNA-free
hetero-oligomers EzFzG, D1zD2, and B/B9zD3 (3–6). After the
nuclear export of the RNA polymerase II transcripts U1, U2,
U4, and U5, the Sm protein complexes assemble on the Sm site,
a conserved sequence that these UsnRNAs have in common (7).
Interestingly, single Sm proteins do not bind to the UsnRNA.
Rather, the D1zD2 and EzFzG complexes first bind to the Sm
site, thus forming a so-called subcore snRNP intermediate.
Subsequent association of the B/B9zD3 complex completes the
formation of the core UsnRNP. The core UsnRNP is required
for the hypermethylation of the m7G cap of the U1, U2, U4, and
U5 snRNAs to m3G caps (8, 9) and also constitutes part of the
bipartite nuclear localization signal necessary for the import of
the UsnRNPs into the nucleus (10, 11). Moreover, there is
evidence that the Sm proteins may stabilize the association of
specific snRNP proteins (12).
Sm proteins are not only of functional interest but also of
clinical relevance. Patients suffering from the autoimmune
disease systemic lupus erythematosus (SLE) spontaneously
produce autoantibodies against a multitude of cellular compo-
nents (13–15). Antibodies against Sm proteins (anti-Sm au-
toantibodies) are SLE-specific, in contrast to most other SLE-
associated autoantibody populations. Therefore, the elu-
cidation of the antigenic determinants recognized on the Sm
proteins is of significant diagnostic and immunopathological
relevance.
In immunoblots, anti-Sm autoantibodies react predomi-
nantly with the Sm proteins B/B9, D1, D3, and, to a lesser
extent, D2 (16, 17). The E, F, and G proteins are also frequently
recognized under native conditions, such as in immunoprecipi-
tation assays (18). The parallel recognition of several Sm pro-
teins by anti-Sm patient sera is not only due to distinct anti-
body populations but also to cross-reactive epitopes on the Sm
proteins (16, 19), thus indicating that the Sm proteins share
structural homology. Indeed, all Sm proteins are evolutionarily
conserved in an approximately 70–90-amino-acid-long region
designated the Sm domain, which contains the Sm1 and Sm2
motifs (3, 20, 21). The recent elucidation of the crystal struc-
tures of the BzD3 and D1zD2 complexes demonstrated that the
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fold of the Sm domain is also highly conserved (22). Epitope
mapping studies with the Sm proteins B/B9 and D1 have dem-
onstrated that the Sm domains of these proteins indeed form
discontinuous B-cell epitopes (23, 24). However, some putative
linear epitopes have also been mapped on the Sm proteins D1
and B/B9. These epitopes are predominantly located in the
C-terminal extensions of the D1 and B/B9 proteins and not in
the Sm domain (25). The C terminus of D1, for example, which
contains a stretch of nine RG dipeptides (26), was reported to
form an epitope for anti-Sm autoantibodies (23, 27–30). How-
ever, in contrast to the native D1 protein, the C-terminal
epitope of D1 often reacted with autoantibodies from patients
with other diagnoses than SLE (30). Therefore, the disease-
specific recognition of the D1 C terminus by anti-Sm autoanti-
bodies seems not only to be sequence-dependent but could
additionally depend on other factors such as proper folding
and/or posttranslational modifications.
C-terminal RG dipeptide repeats are found in D1 and D3
orthologs of most organisms except yeast, suggesting that the
RG stretches of D1 and D3 play an important functional role in
higher eukaryotes. RG-rich regions are also found in several
other nuclear proteins that are involved in RNA processing (e.g.
heterogeneous nuclear ribonucleoprotein A1, fibrillarin,
nucleolin, and the yeast-RNA binding protein Np/3p (for a
review, see Ref. 31)). However, in contrast to D1 and D3, they
contain RGG motifs. Interestingly, the glycine/arginine-rich
motifs of these proteins commonly contain asymmetrical dim-
ethylarginines (aDMAs), a posttranslational modification
formed by type I protein arginine N-methyltransferases (31).
We surmised that methylation of arginines in D1 could not only
explain why synthetic RG-rich D1 peptides often react unspe-
cifically (30) but also why human D1 protein reacts only weakly
and sometimes unspecifically with anti-Sm autoantibodies
when overexpressed in E. coli (32–34). We therefore analyzed
the Sm proteins D1 and D3 for posttranslational modifications
and investigated the influence of such modifications on their
antigenicity. Using protein sequencing and mass spectrometry,
we could demonstrate that the human Sm proteins D1 and D3
are dimethylated in vivo in all nine and four positions, respec-
tively, of their C-terminal RG-stretches. In contrast to other
nuclear proteins, D1 and D3 contain symmetrical dimethyl-
arginines (sDMAs), a posttranslational modification thus far
only identified in the myelin basic protein (MBP). In epitope
mapping studies, a synthetic C-terminal peptide of D1 that
contained sDMA reacted with 10 of 11 anti-Sm patient sera and
the monoclonal antibody Y12, while homologous peptides with
aDMA or nonmodified arginines were not recognized. Our data
thus demonstrate that the recognition of D1 by anti-Sm au-
toantibodies and Y12 is strongly dependent on the symmetrical
dimethylation of the C terminus of D1.
EXPERIMENTAL PROCEDURES
Patient Sera—Sm-positive patient sera (n 5 11) were obtained from
the Department of Rheumatology, Ghent University Hospital (Ghent,
Belgium). Selection of Sm-positive sera was based on the use of the
INNO-LIAy ANA (Innogenetics N.V., Ghent, Belgium), a line immu-
noassay (LIA) containing natural SmD derived from purified HeLa
UsnRNPs. Control sera tested negative for anti-nuclear factor in indi-
rect immunofluorescence on Hep2 cells and showed no reactivity on the
INNO-LIAy ANA.
Isolation of Sm Proteins and Protein Sequencing—Purification of
HeLa UsnRNPs and subsequent separation of Sm proteins by SDS-
polyacrylamide gel electrophoresis have been described earlier (16).
Coomassie Blue-stained bands of the respective Sm proteins were ex-
cised and directly submitted to proteolytic digestion according to Rosen-
feld et al. (35). Briefly, the excised gel slices were washed twice with 2
ml of water for 1 h and then shaken strongly in an aqueous solution (pH
6.4) of 40% acetone, 10% triethylamine, and 5% acetic acid for 2 h. After
washing three times for 1 h with 2 ml of water, the gel slices were dried
and proteolytically digested with 0.5–2.0 mg of endoproteinase Lys-C
(Roche Molecular Biochemicals) in 200–500 ml of digestion buffer (100
mM Tris-HCl, pH 8.0, 10% acetonitrile, 1 mM K3EDTA). The peptide
mixture was separated by HPLC on a C4 column (Vydac, Hesperia, CA)
using a 10–70% gradient of solvent B (70% acetonitrile, 0.1% trifluoro-
acetic acid). Manually recovered peptide fractions were then sequenced
by Edman degradation using a Procise 492 sequencer equipped with an
on-line 140C phenylthiohydantoin analyzer (Perkin-Elmer). To distin-
guish methylated arginines from nonmethylated arginines, we first
applied a combination of either monomethylarginine (MMA) and sDMA
or MMA and aDMA to a biobrene-coated, trifluoroacetic acid-treated
glass fiber filter (Perkin-Elmer) and performed an Edman degradation
cycle for each combination. Next, the human C-terminal D1 peptide, the
C-terminal D3 peptide, or the baculo-derived C-terminal peptide was
applied on the same filter and sequenced to completion. All additional
standards were purchased from Sigma.
Overexpression and Purification of D1 in Escherichia coli and Bacu-
lovirus-infected Insect Cells—A cDNA containing the sequence of hu-
man D1 (26) was inserted as a BamHI/XbaI fragment into the expres-
sion vector pIGFH111 (Innogenetics), thus introducing the first 25
amino acids of mouse tumor necrosis factor and six histidines to the
amino terminus of D1. After transfection into the E. coli strain SG4044
(pc1857) and temperature induction, a strong protein band in the ex-
pected range of 18 kDa could be detected in the soluble fraction. This
protein was verified to be recombinant D1 by immunoblotting with an
anti-tumor necrosis factor antibody (Innogenetics). After lysing the cells
by French pressing in lysis buffer (10 mM Tris-HCl, pH 6.8, 100 mM KCl,
25 mM e-aminocaproic acid, 1 mM dithiothreitol, 2 mM phenylmethyl-
sulfonyl fluoride) and centrifugation at 4 °C (20 min at 27,000 3 g),
guanidinium HCl was added to the supernatant to a final concentration
of 4.5 M, and recombinant protein was purified by affinity chromatog-
raphy on a nickel column (nickel-Sepharose; Amersham Pharmacia
Biotech).
For overexpression of D1 in baculovirus-infected insect cells, a 520-
base pair DraI–SbaI fragment of pIGFH111hSmD1 (see above) was
inserted into a BamHI–XbaI-digested baculovirus transfer plasmid
pVL1393 (Pharmingen, San Diego, CA) in which the fusion gene is
under transcriptional control of the strong baculovirus polyhedrin pro-
motor. After transfection of the vector (as described by the manufactur-
er), a D1 protein was expressed, as evidenced by immunoblotting (see
above). After lysis, baculo-derived D1 was purified on a nickel column
as described above.
Mass Spectrometry—Matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry of the C-terminal D1
peptide was performed on a Voyager-DE STR (PerSeptive Biosystems,
Framingham, MA) mass spectrometer equipped with delayed extrac-
tion and operated at an accelerating voltage of 20 kV and 150-ns delay.
Desorption and ionization of the sample was carried out with a nitrogen
laser (337 nm). Samples were applied on a stainless steel sample plate
using the thin layer method (36) and measured in reflectron mode.
MALDI-TOF-obtained spectra were externally calibrated using a stand-
ard peptide mixture of angiotensin I 1296.6853 [M 1 H]1, ACTH-(1–17)
2093.0867 [M 1 H]1, ACTH-(18–39) 2465.1989 [M 1 H]1, and ACTH-
(7–38) 3657.9294 [M 1 H]1. The observed mass peaks were annotated
manually. Electrospray mass spectrometry of recombinant D1 was per-
formed in a Bio-Q-quadrupole mass spectrometer equipped with an
electrospray ion source (Micromass, Wytenshawe, United Kingdom).
For analysis, 20 pmol of protein or peptide were applied in 10 ml of 50%
acetonitrile, 1% acetic acid. Calibration was performed with 50 pmol of
horse heart myoglobin.
Peptide Synthesis and LIA—Peptides were synthesized on Tentagel
S resin (Rapp Polymere GmbH, Germany) using a Rainin Symphony
Multiplex synthesizer (Protein Technologies, Tucson, AZ) with stand-
ard Fmoc chemistry. Standard double couplings were performed by
using a 4-fold excess of Fmoc-protected amino acids activated in situ
with equimolar amounts of N-hydroxybenzotriazole and 2-(1H-benzo-
triazole-1-yl)-1,1,3,3,-tetramethyluronium tetrafluoroborate twice for
20 min each time. Fmoc-protected asymmetrical and symmetrical dim-
ethylarginine (Bachem, Switzerland) were incorporated similarly. After
completion of the peptide synthesis, the peptide was cleaved from the
resin by incubation for 2.5 h with a mixture of 90% trifluoroacetic acid,
5% thioanisole, 3% ethanedithiol, and 2% anisole. The peptide was
precipitated from the mixture using t-butyl methyl ether. After centrif-
ugation, the pellet was washed three times with t-butyl methyl ether
and dried overnight in a vacuum. The purity of the crude peptide was
checked by reversed-phase HPLC.
For LIA, purified, gel-eluted HeLa proteins, from which SDS and
Coomassie were removed by ion pair extraction (16) or purified recom-
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binant proteins were sprayed as lines on a nylon membrane with a
plastic backing and treated as described previously (37). Patient sera
and Y12 were applied in a dilution of 1:200. A 3-fold molar excess of
biotinylated synthetic peptides in 50 mM sodium carbonate buffer (pH
9.6) were complexed to streptavidin by incubating for 1 h at 37 °C,
before applying to the membrane. In order to visualize the applied
proteins or peptides, a nonblocked LIA strip was stained with colloidal
gold (Aurodye; Amersham Pharmacia Biotech) according to the manu-
facturer’s procedure.
RESULTS
The Human Sm Proteins D1 and D3 Contain sDMAs at Their
Carboxyl Termini—To investigate whether the RG-rich
stretches of the human D1 and D3 proteins contain methylated
arginines, we performed protein sequencing and mass spec-
trometry. HeLa UsnRNPs were initially purified by immuno-
affinity chromatography with an H2O antibody directed
against the m3G cap of UsnRNPs (38), and the protein constit-
uents of the human UsnRNPs were then fractionated by High-
TEMED SDS-polyacrylamide gel electrophoresis (16). Subse-
quently, those bands containing the D1 and D3 proteins were
excised from the gel and proteolytically digested with endo-
Lys-C. This procedure resulted in a C-terminal 29-amino acid-
long D1 fragment (amino acids 91–119) and a 23-amino acid-
long D3 fragment (amino acids 105–124) (see Fig. 1). After
fractionation of the D1 and D3 peptide mixtures by HPLC, we
were able to isolate both C-terminal peptides, so that all C-
terminal RG dipeptides of D1 and D3 were analyzed (Fig. 1).
To initially determine whether the C-terminal peptide of D1
contains posttranslational modifications, we performed mass
spectrometry (MALDI-TOF). A protonated major mass peak,
isotopically resolved at 3366.68 Da, was detected (Fig. 2). The
observed value clearly deviated from the theoretical mass ex-
pected for a nonmodified D1-(91–119) peptide. Moreover, the
mass difference fit almost perfectly for a D1 peptide with dim-
ethylated arginines at all positions of its RG-rich stretch (the
theoretical protonated monoisotopic value of D1-(91–119) with
nine DMAs is 3366.10 Da). A minor peak of 3238.58 Da, ob-
tained to a lesser extent after proteolytical digestion, was also
observed and is consistent with a dimethylated D1-(92–119)
peptide (Fig. 2). Two additional peaks of 3252.85 and 3380.65
Da corresponded to D1-(92–119) and D1-(91–119) peptides
with an additional methyl group, due to esterification of the
carboxyl termini upon storage in an acidified methanolic solu-
tion. The MALDI-TOF analysis of D1 thus not only demon-
strated the presence of posttranslational modifications in the C
terminus of D1, but also strongly suggested the presence of
DMAs.
To confirm the results of our mass spectrometry experiments
and to distinguish between asymmetrically and symmetrically
dimethylated arginines (see Fig. 3), we analyzed the C-termi-
nal D1 and D3 peptides by protein sequencing. For this pur-
pose, we not only used the normal PTH-derivative standard
during the sequencing run but additionally applied MMA,
aDMA, and sDMA as a standard for the HPLC-based identifi-
cation of amino acids. Fig. 3A shows an alignment of the Ed-
man degradation cycles of the gel-purified C-terminal peptide
of HeLa D1 with the HPLC elution profiles of PTH-modified
MMA, aDMA, and sDMA (indicated by arrows). We obtained a
clear separation of arginine, MMA, aDMA, and sDMA (Fig. 3, A
and B). When we compared the elution profiles of the C-termi-
nal peptide of HeLa D1 with the applied standards, we could
reproducibly identify symmetrical DMAs in the C terminus of
D1. As emphasized by the cycle numbers in Fig. 3A (only the
cycles corresponding to the arginines are shown), sDMA is
present at all nine positions in the RG-rich stretch of D1. Only
the arginines at positions 2, 28, and 29 of the D1 peptide
(positions 92, 118, and 119 of D1), which are not flanked by
glycines, were not dimethylated (data not shown), thus provid-
ing evidence that the methyltransferase modifying D1 recog-
nizes solely its RG repeat. In agreement with our mass spec-
trometry experiments (Fig. 2), we could not observe even minor
peaks corresponding to arginine or MMA (see Fig. 3A). The
absence of detectable amounts of undermethylated D1 precur-
sors in HeLa nuclear extracts may hint at a cytoplasmic local-
ization of the D1-modifying methyltransferase.
In the D3-derived peptide encompassing amino acid residues
105–124, four symmetrically methylated arginines at positions
FIG. 1. Location of sDMAs in the amino acid sequences of the Sm proteins D1 and D3. The RG stretches are presented in boldface type,
and sDMAs are indicated by asterisks. The position of the Sm 1 and Sm 2 motifs is shown by the consensus sequence below the protein sequences.
Sequenced C-terminal D1 and D3 fragments obtained by proteolytic digestion with endo-Lys-C are indicated by arrows.
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110, 112, 114, and 118 of the D3 protein were identified (data
not shown). Interestingly, the sDMA at position 110 of D3, in
contrast to all other modified arginines in the RG-rich stretches
of D1 and D3, was not preceded by a glycine (alanine instead of
glycine; see Fig. 1). This raised the possibility that such RG
dipeptides generally could serve as substrates for posttransla-
tional methylation. However, RG dipeptides present in the Sm
motif 2 of D1 and D3 (amino acid 61 in D1 and 64 in D3; Fig. 1)
were not modified. Also, methylated arginines were not found
in the single RG dipeptides present in the Sm proteins E, F, G,
and D2 (data not shown). As observed with D1, the sDMA
precursors arginine and MMA were not detected in D3. These
results thus demonstrated that, in contrast to several RGG
box-containing proteins that contain asymmetrical DMA, the
human Sm proteins D1 and D3 are symmetrically dimethyl-
ated. Moreover, since we isolated the D1 and D3 proteins from
biochemically purified HeLa UsnRNPs, symmetrical dimethy-
lation of D1 and D3 occurs in vivo.
Recombinant D1 from E. coli and Baculovirus-infected Insect
Cells Is Only Poorly Recognized by Anti-Sm Patient Sera in
LIAs—D1 overexpressed in E. coli has been reported to react
only weakly and sometimes unspecifically with patient sera
(see Introduction). Moreover, the prototypical anti-Sm anti-
body, Y12 (39), strongly reacted with native D1, D3, and B/B9 in
immunoblots but not with recombinant D1 overexpressed in E.
coli (Ref. 16 and data not shown). It was thus conceivable that
the B-cell epitopes recognized by Y12, and by at least some
anti-Sm autoantibody populations, require sDMA for efficient
recognition. To investigate this hypothesis, we overexpressed
D1 in either E. coli or in baculovirus-infected insect cells. For
one-step purification by nickel affinity chromatography, both
proteins were overexpressed as fusion proteins containing the
FIG. 2. MALDI-TOF mass spectrum
of an HPLC-purified fraction con-
taining the modified arginine C-ter-
minal peptide that was obtained by
endo-Lys-C digestion of human D1.
FIG. 3. A, PTH-derivative sequence
analysis of an HPLC-purified fraction
containing the C-terminal peptide gener-
ated by endo-Lys-C digestion of human
D1. An alignment is shown of the Edman
degradation cycles 8, 10, 12, 14, 16, 18, 20,
22, and 24 (corresponding to arginines in
positions 98, 100, 102, 104, 106, 108, 110,
112, and 114 of D1). The elution profiles of
MMA, aDMA, and sDMA are indicated by
arrows. The structure of sDMA is shown
on the right. B, PTH-derivative sequence
analysis of an HPLC-purified fraction
containing the C-terminal peptide gener-
ated by endo-Lys-C digestion of baculo-
derived D1. The same Edman degrada-
tion cycles as in A are aligned. The
structure of aDMA is shown on the right.
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first 25 amino acids of mouse tumor necrosis factor and six
histidines (see “Experimental Procedures”). In electrospray
mass spectrometry, we observed a mass of 17,435 Da for the E.
coli-derived D1, which was the expected mass for the full-size
fusion protein without any posttranslational modifications. In
contrast, the purified D1 from the baculovirus expression sys-
tem yielded several peaks with significantly higher masses
(data not shown), thus providing evidence that posttransla-
tional methylation of recombinant D1 had taken place. To
further investigate the dimethylation status of the baculo-de-
rived D1, we performed protein sequencing as described for the
HeLa-derived D1 protein (see Fig. 3B). Although we could
isolate a minor HPLC fraction containing nonmodified peptide
D1-(91–119), the majority of the baculo-derived D1 was indeed
dimethylated, as predicted by the mass spectrometry (see
above). However, in contrast to the HeLa-derived D1 protein,
the baculo-derived protein contained asymmetrical, as opposed
to symmetrical, dimethylarginines (see Fig. 3B). The less prom-
inent peaks preceding the aDMAs in the HPLC elution profiles
in Fig. 3B co-eluted with the dimethylation precursors, argi-
nine and MMA.
To analyze the immunological properties of the recombinant
D1 proteins, we applied equal amounts of baculo-derived D1, E.
coli-derived D1, and a mixture of gel-purified human D1, D2,
and D3 (HeLa D1/D2/D3 in Fig. 4A), which served as a positive
control, to nylon strips. The strips were then incubated with
anti-Sm sera from SLE patients and the monoclonal anti-Sm
antibody Y12. As negative controls, we used sera from patients
with mixed connective tissue disease, containing high titers of
anti-RNP autoantibodies against the U1-A, U1-C, and U1–70K
proteins (RNP-positive in Fig. 4) as well as sera from healthy
patients that did not contain antinuclear autoantibodies (ANA-
negative in Fig. 4). While a mixture of D1, D2, and D3 from
HeLa cells reacted significantly with all of the tested anti-Sm
patient sera, the E. coli-derived D1 gave only weak signals,
which were in the intensity range of signals obtained with
control sera (compare D-positive sera with ANA-negative and
RNP-positive sera in Fig. 4A). Interestingly, also the baculo-
derived D1 reacted only weakly with anti-Sm patient sera; only
four bands of significant intensity were observed with baculo-
derived D1 (sera Sm56, Sm83, Sm111, and Sm130 in Fig. 4A).
Note that similar amounts of antigen had been applied to the
strips, as controlled by aurodye staining (Fig. 4A, lane 1). To
verify that the tested anti-Sm patient sera contained anti-D1
autoantibodies, we additionally tested the patient sera with
single HeLa-derived D1, D2, and D3 proteins in LIA (Fig. 4B).
Except for serum Sm124, which reacted exclusively with D2
(Fig. 4B, lane 3), all anti-Sm sera reacted significantly with
HeLa-derived D1, including those that did not react with ba-
culo-derived D1 (compare, for example, Sm34; lane 5 in Fig. 4,
A and B). Although we cannot fully exclude the possibility that
the weak antigenicity of the recombinant D1 proteins was due
to the extra amino acids of the fusion region, the less frequent
recognition of both E. coli-derived and baculo-derived D1 indi-
cated that the presence of sDMAs strongly increases the anti-
genicity of the D1 protein.
Anti-Sm Patient Sera Specifically Recognize the sDMA-con-
taining Carboxyl Terminus of D1—The predominant recogni-
tion of HeLa-derived D1 in LIA strongly suggested that the
symmetrically dimethylated C terminus of D1 forms a B-cell
epitope for anti-Sm autoantibodies. To analyze this, we chem-
ically synthesized peptides containing nine aDMAs, nine sD-
MAs, or nine arginines in the in vivo methylated positions and
used them as antigens in LIA experiments with the aforemen-
tioned patient sera. All peptides were purified by HPLC and
characterized by mass spectrometry. The presence of sDMA
was demonstrated by sequencing. To ensure efficient binding of
the peptides to the membrane, we conjugated them with an
N-terminal biotin residue during peptide synthesis and formed
a streptavidin-peptide complex before applying the antigens to
FIG. 4. LIA with patient sera and different Sm antigen sources. The strips were tested with 11 anti-Sm patient sera (SmD-positive), five
anti-RNP sera from patients with mixed connective tissue disease (RNP-positive), and five control sera that were found negative for anti-nuclear
antibodies (ANA-negative). The designations of the sera are indicated at the top. The antigen sources are indicated to the left. The amount of applied
antigen is indicated to the right. A, baculo-derived D1, E. coli-derived D1, and a mixture of gel-purified human D1, D2, and D3 from HeLa cells
were applied to the strips at a concentration of 7.5, 15, and 30 ng/line. B, 15 ng of gel-purified, human D1, D2, or D3 protein from HeLa cells were
applied as antigen source. C, line immunoassay with synthetic peptides, encompassing the D1 amino acids 95–119. Peptide D1-(95–119) Arg
contained nonmodified arginines instead of sDMA in the in vivo dimethylated positions. Peptide D1-(95–119) aDMA contained aDMA instead of
sDMA. Peptide D1-(95–119) sDMA contained sDMA in the in vivo dimethylated positions. All peptides were applied to the membrane at a
concentration of 15 ng/line.
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the membrane. Indeed, the complexed peptides bound well to
the membrane (Fig. 4C, lane 1). As shown in Fig. 4C, 10 of 11
anti-Sm patient sera significantly reacted with the sDMA-
containing peptide. In contrast, peptides with either arginine
or aDMA were not recognized by anti-Sm patient sera. These
data not only demonstrate that anti-Sm autoantibody popula-
tions frequently recognize the C terminus of D1 directly but
also show that the efficient recognition of this epitope is de-
pendent on the presence of sDMA. Since sera from mixed
connective tissue disease patients with high titers of anti-RNP
autoantibodies and control sera from healthy patients did not
react with the sDMA-containing peptide, the reaction was SLE-
specific. The specificity of the LIA was further substantiated by
the finding that the only anti-Sm patient serum that did not
react with the peptide was a serum that exclusively reacted
with D2 (see Fig. 4, B and C, lane 3). The negative signal
observed with this serum was thus due to the absence of an-
ti-D1 autoantibodies. Strikingly, the monoclonal antibody Y12
also reacted with the peptide D1-(95–119) sDMA, but not with
D1-(95–119) Arg or D1-(95–119) aDMA (Fig. 4C, lane 13). Pre-
vious studies using synthetic peptides or E. coli-derived dele-
tion mutants had always failed to generate significant signals
with this antibody (see “Discussion”). Our results indicate that
Y12 also requires sDMA for antigen recognition, at least in the
epitope localized on D1. Moreover, since an sDMA-containing
RG-rich stretch is also present in the D3 protein, an epitope in
this region can easily explain the cross-reactivity of Y12 and
anti-Sm autoantibodies with D1 and D3.
DISCUSSION
In this paper, we demonstrate by protein sequencing and
mass spectrometry that the human Sm proteins D1 and D3 are
symmetrically dimethyated at C-terminal arginines in vivo.
This is the first time that posttranslational modifications have
been localized in Sm proteins. The presence of the unusual
amino acid sDMA in D1 and D3 could have implications both
for snRNP biogenesis and SLE etiology.
The elucidation of the antigenic determinants recognized by
anti-Sm autoantibodies is of considerable interest to under-
stand and diagnose the autoimmune disease SLE (see Intro-
duction). In antibody binding studies, we could clearly identify
a linear epitope for anti-Sm autoantibodies and the monoclonal
antibody Y12 on the amino acids 95–119 of the human D1
protein. Importantly, the intensities of the signals observed
with the D1 peptide 95–119 containing sDMA were in the
range of the signals obtained with the native D1 protein (Fig. 4,
compare B and C). Previous studies have also mapped an
epitope for anti-Sm autoantibodies at the C terminus of D1 (23,
27–29, 40). However, in these studies, the analyzed D1 frag-
ments did not contain sDMA and were not compared with a
wild type protein, raising the possibility that the binding of
anti-Sm autoantibodies was only weak. Indeed, in our hands, a
nonmodified D1 peptide 95–119 and an aDMA-containing pep-
tide 95–119 showed only basal level signal intensities, as com-
pared with the native D1 protein (Fig. 4). Our data thus dem-
onstrate that the presence of sDMA strongly increases the
affinity of anti-Sm autoantibodies for the C terminus of D1.
The sDMA-containing peptide D1-(95–119) is the first syn-
thetic peptide found to significantly react with the prototypical
anti-Sm antibody Y12 (Fig. 4C). Deletion mutagenesis, using in
vitro translated proteins, has located the Y12 epitope to the C
termini of the Sm proteins D1 and B/B9 (24, 41) and the ribo-
somal S10 protein (42), all of which contain at least one GRG
tripeptide. However, neither synthetic peptides encompassing
the mapped epitopes nor E. coli-derived D1, D3, or B/B9 reacted
significantly with Y12 (24).2 Our data therefore suggest that
symmetrically dimethylated RG stretches constitute a major
Y12 epitope. The dimethylation status of B/B9 or S10 is not yet
clear; however, the presence of GRG tripeptides in the mapped
Y12 epitopes of these proteins raises the possibility that they
may also contain sDMA. However, although protein sequencing
of single RG dipeptides in the E, F, and G proteins revealed
that these proteins are not dimethylated (data not shown), an
EzFzG complex is significantly immunoprecipitated by Y12 (18).
This indicates that Y12 may recognize more than one epitope
on the Sm proteins.
The high efficiency by which the sDMA-containing peptide is
recognized by anti-Sm autoantibodies and Y12 demonstrates
that the C-terminal, linear epitope contributes significantly to
the antigenicity of the full-length human D1 protein. Accord-
ingly, the E. coli-derived D1, which contained nonmodified
arginines was not recognized by anti-Sm autoantibodies (Fig. 4,
compare A and C). However, 4 of 11 anti-Sm sera significantly
reacted with the aDMA-containing baculo-derived D1 but not
with the aDMA-containing peptide. This indicates that the
baculo-derived D1 contains additional epitopes, e.g. discontin-
uous epitopes on the Sm domain (see Introduction), that were
recognized by anti-Sm autoantibodies. Ou et al. (32) reported
that 96% of anti-Sm patient sera recognized recombinant D1
overexpressed in baculovirus-infected insect cells in enzyme-
linked immunosorbent assays, while 71% of patient sera rec-
ognized D1 overexpressed in E. coli. The increased antigenicity
of the baculo-derived D1 as compared with the E. coli-derived
D1 suggests that the asymmetrical dimethylation of D1 in the
former case stabilizes conformational epitopes on the Sm do-
main. The same may be true for the symmetrical dimethyl-
arginines. The lower frequency of recognition of the recombi-
nant D1 proteins in our LIA as compared with the study of Ou
et al. could therefore be due to the increased degree of renatur-
ation in the enzyme-linked immunosorbent assay protocol used
by Ou et al. (Ref. 32; see also Ref. 40). However, since both the
HeLa-derived D proteins and the peptide D1-(95–119) sDMA
were recognized with a high frequency (10/11) and specificity
by patient sera in our study, native Sm proteins and the sDMA-
containing peptide are interesting substrates for the diagnosis
of SLE. Studies to investigate the specificity and sensitivity of
anti-Sm autoantibody detection in an extended SLE patient
population, using the peptide D1-(95–119) sDMA as an anti-
gen, are currently under way.
Little is known about the etiology of SLE and other autoim-
mune diseases. We have demonstrated that symmetrical dim-
ethylation can increase the affinity of anti-Sm autoantibodies
toward their antigenic target. Similarly, a class of rheumatoid
arthritis-associated autoantibodies (APF/AKA) reacted exclu-
sively with citrulline-containing peptides of the rheumatoid
arthritis autoantigen filaggrin but not with homologous argin-
ine-containing peptides (43, 44). Autoantigens containing
asymmetrically dimethylated arginines have also been de-
scribed: fibrillarin in scleroderma (45), heterogeneous nuclear
ribonucleoprotein A1 in connective tissue diseases (46), and
nucleolin in SLE (47). It is therefore tempting to speculate that
posttranslational modifications might play a role in the etiol-
ogy of SLE and other autoimmune diseases. Recently, much
attention has been paid to posttranslational protein modifica-
tions during apoptotic processes, which may lead to the subse-
quent development of autoantibodies (48). Abnormal apoptosis,
such as observed in SLE (for a review, see Ref. 49), could result
in the continuous presentation of modified autoantigens that
are normally retained in the nucleus (50). During apoptosis,
2 H. Brahms and R. Lu¨hrmann, unpublished observations.
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nuclear, dimethylated D1 could induce an autoimmune re-
sponse in an antigen-driven manner. To investigate this hy-
pothesis, it will be of considerable interest to analyze the im-
munogenicity of the dimethylated C terminus of D1 in animal
models.
The D1 and D3 proteins are the first examples of human
nuclear proteins that are symmetrically dimethylated in vivo.
Other dimethylated nuclear proteins contain asymmetrical
DMAs (see Introduction). Indeed, the only other human protein
shown to contain sDMA to date is MBP, which is a major
component of the nerve sheath and implicated in the autoim-
mune disease multiple sclerosis (51). This raises the question of
which protein arginine N-methyltransferase is responsible for
the methylation of the D1 and D3 proteins. Type I methyltrans-
ferase, which was recently cloned from yeast (52), rat (53) and
humans (54), catalyzes the formation of aDMAs in histones and
heterogeneous nuclear ribonucleoprotein A1 (for a review, see
Ref. 31). In contrast, the gene for the type II methyltransferase
that specifically modifies MBP to create sDMAs has not yet
been identified. The symmetrical dimethylation of D1 and D3
would suggest that these proteins are substrates for a type II
methyltransferase. MBP contains only a single sDMA at posi-
tion 107 (51), and the amino acid sequence surrounding Arg-
107 (104GKGRGL109) slightly resembles the D1 RG repeat.
Interestingly, a heptapeptide with alternating glycines and
arginines (GRGRGRG), such as found in D1, was the most
effective methyl acceptor for a partially purified MBP-specific
type II protein methyltransferase (55). However, only MMA
with a minor fraction of aDMA was formed in vitro with this
peptide, providing evidence that methyltransferases may
change their activity dependent on the substrate. It is therefore
possible that proper dimethylation of D1 and D3 requires a
particular hetero-oligomeric protein environment, e.g. assem-
bled core UsnRNPs or Sm protein complexes (see Introduction).
Proper assembly as a prerequisite for proper dimethylation
could easily explain our observation that baculo-derived D1
contained aDMA instead of sDMA (see Fig. 3B), since the
overexpressed D1 protein does not come in contact with stoi-
chiometric amounts of the other Sm proteins or UsnRNA to
form the D1zD2 complex or core UsnRNPs. To unambiguously
identify and characterize the D1/D3-modifying enzyme, de-
tailed in vitro methylation studies with recombinant and/or
purified methyltransferases and with different substrates
(such as the heteromeric protein complexes involved in Sm core
formation) will be necessary.
The biological function of arginine methylation is largely
unknown. The strongly increased binding of Y12 and anti-Sm
autoantibodies to D1 in the presence of sDMA suggests that the
methylation of the D1 and D3 proteins may modulate interac-
tions with other cellular components. In the case of MBP, the
sDMA at position 107 is indeed involved in the integrity and
compactness of myelin. Moreover, it has been demonstrated
that the MBP-specific methylase activity occurs concurrently
with the myelination process (for a review, see Ref. 56). Like-
wise, the methylation of D1 and D3 could stabilize or weaken
protein-protein or protein-RNA interactions, thus regulating
the biogenesis of UsnRNPs. The formation of complexes be-
tween the Sm proteins (see Introduction) is probably not af-
fected by arginine methylation, since the yeast D1 and D3
homologues, which form equivalent complexes, lack an RG-rich
stretch (57, 58). In addition, it has been demonstrated for the
human Sm proteins that the Sm domain alone is sufficient for
complex formation (3, 22). However, arginine methylation
could be involved in the binding of the Sm core to UsnRNP-
specific proteins (12) or could reduce unspecific protein-RNA
interactions of D1 and D3 by steric hindrance (59). It has also
been suggested that methylated arginines may facilitate trans-
port events (60). Since one part of the bipartite nuclear local-
ization signal of the UsnRNPs is situated on the core proteins
(10, 11), it is possible that arginine methylation facilitates the
binding of the properly assembled core-UsnRNP to a still uni-
dentified nuclear import factor. Consistent with this possibil-
ity, our data suggest that methylation of D1 takes place in the
cytoplasm, since all D1 molecules we isolated from nuclear
extracts were completely dimethylated. If methylation were to
occur in the nucleus, minor amounts of unmodified arginine
and MMA would be expected at positions 98–114 of D1. To
understand the biological function of the symmetrical dimethy-
lation of the D1 and D3 proteins, it will therefore be of consid-
erable interest to analyze the cytoplasmic assembly intermedi-
ates of the UsnRNPs for dimethylated arginines.
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